| Document |
Document Title |
|
WO/2019/242691A1 |
Provided are a paclitaxel-lipid-polysaccharide dual-type conjugate related to general formula I, a preparation method therefor, a use thereof, and a pharmaceutical composition comprising same. The present invention also relates to a seri...
|
|
WO/2019/245910A1 |
The present invention relates to triazine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by adminis...
|
|
WO/2019/242687A1 |
The present invention discloses a 1,3-dioxane-4,6-dione compound, and a preparation method, a pharmaceutical composition, and an application thereof. The structure of the compound is represented by formula I, and the definition of each s...
|
|
WO/2019/245169A1 |
According to various embodiments of the present invention, a method of producing bifunctional furan epoxy (BFFE) can produce BFFE by using bio-based monofunctional furan raw material, the method comprising the steps of: conducting a reac...
|
|
WO/2019/233440A1 |
Disclosed are compounds for the treatment or prevention of liver diseases, which are compounds represented by the general formula (I) or (II), optical isomers or pharmaceutically acceptable salts thereof that can be applied to the prepar...
|
|
WO/2019/229464A1 |
There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depressi...
|
|
WO/2019/232275A1 |
Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be...
|
|
WO/2019/224373A1 |
The present invention relates to the use of 2-furyl-and 2-thienyl-substituted di-and tetrahydropyrans of the formula (I) wherein the variables are as defined in the claims and the description, as aroma chemicals;to aroma chemical composi...
|
|
WO/2019/190409A9 |
There is provided a compound represented by general formula (lb), wherein ring A is a carbocyclic or heterocyclic ring, a reaction product of the reaction between one or more said compounds and one or more amine containing compounds. Als...
|
|
WO/2019/222157A1 |
Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and...
|
|
WO/2019/215633A1 |
The present invention is directed to 5,5-difluoro- and 5-fluoro-5-methyl-C-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more par...
|
|
WO/2019/199667A2 |
The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, pa...
|
|
WO/2019/193062A1 |
The invention discloses compounds of Formula (I) wherein R1, R2, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharm...
|
|
WO/2019/192912A1 |
There is provided a synthesis of [18F]SFB (N-succinimidyl 4-[18F]fluorobenzoate) using a one-step reaction procedure without generating radioactive waste gases. [18F]SFB is useful as a reagent for labeling of low- and high-molecular weig...
|
|
WO/2019/190999A1 |
Disclosed herein are methods of treating fibrotic disorders by administering compounds selective for CAPN1, CAPN2, and/or CAPN9 such that side effects, off pathway interactions, and/or toxicities are minimized. Such methods may, for exam...
|
|
WO/2019/185875A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as herbicides.
|
|
WO/2019/175713A1 |
The present invention relates to the new catechol molecules and their use as inhibitors to P450 related metabolic pathways. The invention further relates to a method of controlling crop pests and/ or non-crop pests that are resistant to ...
|
|
WO/2019/178119A1 |
Disclosed are aminocoumarin compounds, pharmaceutical compositions containing aminocoumarin compounds, and methods of their use, e.g., in the treatment of a Gram- negative bacterial infection.
|
|
WO/2019/171278A1 |
The present invention is directed to heterocycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and / or GPR40 receptors. 5 More particul...
|
|
WO/2019/170543A1 |
The present invention covers heterocyclic compounds of general formula (I) in which T, U, Y, Z, R1 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceuti...
|
|
WO/2019/166003A1 |
The present invention belongs to the technical field of medicine, and discloses use of 14-deoxy-11,12-dehydro-8,12-epoxy-andrographolide and derivatives thereof and 14-deoxy-11,12-dehydro-7,8-ene andrographolide and 15-substituted deriva...
|
|
WO/2019/168170A1 |
The purpose of the present invention is to provide a compound having high binding specificity for amyloid proteins and high blood-brain barrier permeability, and featuring rapid elimination from normal tissues. The present invention rela...
|
|
WO/2019/162458A1 |
The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminyl cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions fo...
|
|
WO/2019/162323A1 |
The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compou...
|
|
WO/2019/161010A1 |
The present invention relates to polycyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R4, R7 to R10, Y and A are as defined herein. The invention also relates to pharmaceutical compositions com...
|
|
WO/2019/160315A1 |
The present invention relates to a heterocyclic compound of formula 1 and an organic light emitting device comprising the same.
|
|
WO/2019/161157A1 |
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).
|
|
WO/2019/156903A1 |
Disclosed are compounds of Formula 1, wherein J is and R1a, R1b, R2, R3, R4, R5, R6, R7, R8, R14, R15, R16, Q and X are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for c...
|
|
WO/2019/154663A1 |
The present invention relates to the use of compounds of formula I, wherein the variables are defined as given in the description and claims. The invention further relates to the compounds I and composition for compounds of formula I.
|
|
WO/2019/150305A1 |
Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and compounds (I) for use as inhibitors of the KRAS protein for the tretament of cancer.
|
|
WO/2019/145719A1 |
The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of For...
|
|
WO/2019/138332A1 |
Process for the preparation of a disubstituted diaryloxybenzoheterodiazole compound having general formula (I).
|
|
WO/2019/134667A1 |
A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically accep...
|
|
WO/2019/121691A1 |
The present disclosure relates to compounds of Formula (I): (I) and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for...
|
|
WO/2019/126505A1 |
This application relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, which are inhibitors of ΡΙ3Κ-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular dis...
|
|
WO/2019/121159A1 |
The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description, formula...
|
|
WO/2019/121373A1 |
The present invention relates to the pyrimidine compounds of formula (I), or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are defined according to the description, use of pyrimidine compounds ...
|
|
WO/2019/124903A1 |
An organic light emitting device comprising a compound represented by formula 1 as a light emitting auxiliary layer material and an electronic device comprising the same are disclosed. As the compound represented by formula 1 is comprise...
|
|
WO/2019/122345A1 |
The present invention relates to benzamide compounds of formula I wherein the variables are defined as in the claims and the description, the N-oxides and salts thereof,and to compositions comprising the same. The invention also relates ...
|
|
WO/2019/113693A1 |
Compounds that are inhibitors of retinoic acid inducible P450 (CYP26) enzymes. The compounds have retinoid activity, are resistant to CYP26-mediated catabolism, act as inhibitors of CYP26B1, and are used for treating diseases that are re...
|
|
WO/2019/101719A1 |
The present invention relates to triarylamine compounds according to a defined formula. The present invention further relates to methods for producing said compounds, to the use of the compounds in electronic devices, and to electronic d...
|
|
WO/2019/101039A1 |
Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETA receptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tau...
|
|
WO/2019/099307A1 |
The present technology is directed to compounds, compositions, and methods related to inhibition of ASK1. In particular, the present compounds (e.g., compounds of Formula I as defined herein) and compositions may be used to treat ASK1-me...
|
|
WO/2019/099777A2 |
Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to...
|
|
WO/2019/097487A1 |
The present disclosure relates to derivatives of strigolactone and formulations thereof. The present disclosure also relates to methods of treating a plant to improve, for example, the yield, growth, or vigor of a plant. The disclosed st...
|
|
WO/2019/093623A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting diode using the same.
|
|
WO/2019/085758A1 |
Disclosed in the present invention are a ketone-containing compound and applications thereof in organic electroluminescent devices. The compound consists of ketone and spiroanthracenefluorene groups, has a very deep HOMO energy level and...
|
|
WO/2019/090088A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/081299A1 |
The present invention relates to novel amine substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compos...
|
|
WO/2019/082717A1 |
The purpose of the present invention is to provide: a novel curable compound which can be expected to be used as a raw material for photocurable resins and thermosetting resins; a method for synthesizing said compound; a resin compositio...
|
